PT - JOURNAL ARTICLE AU - Riviere-cazaux, Cecile AU - Carlstrom, Lucas P. AU - Rajani, Karishma AU - Munoz-casabella, Amanda AU - Rahman, Masum AU - Gharibi-Loron, Ali AU - Brown, Desmond A. AU - Miller, Kai J AU - White, Jaclyn J. AU - Himes, Benjamin T. AU - Jusue-Torres, Ignacio AU - Ikram, Samar AU - Ransom, Seth AU - Hirte, Renee AU - Oh, Ju-Hee AU - Elmquist, William F. AU - Sarkaria, Jann N. AU - Vaubel, Rachael A. AU - Rodriguez, Moses AU - Warrington, Arthur AU - Kizilbash, Sani H. AU - Burns, Terry C. TI - Does Blood-Brain Barrier Disruption Define the Glioma Extracellular Metabolome? AID - 10.1101/2021.08.24.21262320 DP - 2023 Jan 01 TA - medRxiv PG - 2021.08.24.21262320 4099 - http://medrxiv.org/content/early/2023/02/15/2021.08.24.21262320.short 4100 - http://medrxiv.org/content/early/2023/02/15/2021.08.24.21262320.full AB - Background The extracellular microenvironment modulates cancer behavior. Although radiographic contrast enhancement is an ominous finding in gliomas, it remains unclear if the associated blood-brain barrier disruption merely reflects or functionally supports tumor aggressiveness.Methods We utilized intra-operative microdialysis to sample the extracellular metabolome of radiographically diverse regions during fifteen neurosurgical resections. The global extracellular metabolome of recovered microdialysate was evaluated via ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) and assessed using enrichment and correlation analyses.Results Among 162 named metabolites identified via ultra-performance liquid chromatography tandem mass spectrometry, guanidinoacetate (GAA), was 126.32x higher in enhancing tumor than in adjacent brain. 48 additional metabolites were 2.05-10.18x more abundant in enhancing tumor than brain. With exception of GAA, and 2-HG in IDH-mutant gliomas, differences between non-enhancing tumor and brain microdialysate were comparatively modest and less consistent. The enhancing but not the non-enhancing glioma metabolome was significantly enriched for plasma-associated metabolites largely comprising amino acids and carnitines.Conclusions Our findings suggest that metabolite diffusion through a disrupted blood-brain barrier may largely define the enhancing extracellular glioma metabolome. Future studies are needed to determine how the altered extracellular metabolome impacts glioma behavior.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04047264Funding StatementNational Institute of Health: T32GM065841 to CRC, TCB was supported by NINDS NRCDP K12, NINDS R61 NS122096, Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor Association, Brains Together for the Cure, Humor to fight the Tumor, and Lucius & Terrie McKelvey. Support was also provided through NCI U54 CA210180 (JS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was conducted under IRB#19-004694 at the Mayo Clinic, Rochester, MN.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data we have collected will be made publicly available upon later submission.2-HG2-hydroxyglutarate2-PYN1-methyl-2-pyridone-5-carboxamideBbrainBBBBlood-brain barrierCNScentral nervous systemCSFcerebrospinal fluidCTcomputed tomographyDFMOdifluoromethylornithineEenhancing tumorFCfold-changeFDRfalse-discovery rateGAAguanidinoacetateGBMglioblastomaGSEAgene set enrichment analysisHGGhigh-grade gliomaHMWhigh molecular weightIDHisocitrate dehydrogenaseINDinvestigational new drugLC/MSliquid chromatography-mass spectrometryNAAN-acetylaspartateNEnon-enhancing tumorODCornithine decarboxylaseWTwild typeUPLC-MS/MSUltra-performance liquid chromatography tandem mass spectrometry